Travere Therapeutics Inc TVTX

$50.24 -0.86 (-1.68%)

Valuation

Market cap
4,905,191,000
Revenue TTM
$490,730,000
Net income TTM
$-25,550,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-5.21%
Debt to equity
0.00

Trading

Volume
884,100
Avg volume
1,973,462
Day's range
$49.80 – $51.40
Shares out
95,992,000
Stochastic %K
47%
Beta
1.11
Analysts
Strong Buy
Price target
$73.43

Price

Company profile

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopron...

Show more

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
888 969 7879
Website
https://www.travere.com
Address
3611 Valley Centre Drive, Suite 300, San Diego, United States

Latest news

Stocktwits

Meigs1865 Nov 18, 3:47 PM
$TVTX this looks like a repeat of yesterday, low volume big dip and then a recovery for the rest of the day until closing.
0 replies
Buckeyeboy722 Nov 17, 9:16 PM
$TVTX Bank of America increased their position by 1.5 million shares last quarter to 6.8 million total shares. They are includes with Blackrock 8 million shares, Fidelity 5.7 million shares, Vanguard 4.1 million shares, Janus Henderson 11.3 million shares.
0 replies
lonelywarrior Nov 17, 8:06 PM
$XBI - $URGN, $TVTX, $RARE holding nice today because fundamentals, revenue and FDA-approved products matter.
0 replies
Meigs1865 Nov 13, 8:26 PM
$TVTX future looks bright. See @Merlintrader analysis. Below is an analysis of 15 Analysts:
1 replies
Merlintrader Nov 11, 5:12 AM
$TVTX Travere (TVTX): FILSPARI sales $200.2M, up 120% year over year Free weekly catalyst newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13 Not investment advice.
0 replies
DeadInvestor Nov 10, 7:44 PM
$TVTX Any information shared at Guggenheim conference this morning? No link was provided to listen in. No transcript available. I don’t expect anything was shared, as TVTX are so opaque in their comms (like not splitting out IgAN vs FSGS indications). Any rationale why the company would avoid being transparent on scripts?
0 replies
GTA_Terminal Nov 8, 6:00 AM
Dark pool check on $TVTX: what traded off the exchanges in the latest session. The stock moved +1.5% on the day, so this wasn't happening in a quiet tape. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=TVTX&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=TVTX Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-check-travere-therapeutics-tvtx?utm_source=stocktwits&utm_medium=social
0 replies
Meigs1865 Nov 5, 6:04 PM
$TVTX Volume is running at half the daily average with 3 hours to closing of the market. No reason for this beatdown other than the overall market reaction to AI and Data Center nonsense by Democrat Socialsts spewing nonsense.
0 replies